share_log

Rapid Dose Therapeutics Corp. Files Patent Application for Lidocaine Oral Thin Strip

Rapid Dose Therapeutics Corp. Files Patent Application for Lidocaine Oral Thin Strip

快速剂量治疗公司提交利多卡因口服薄膜条的专利申请
newsfile ·  12/05 17:24

Burlington, Ontario--(Newsfile Corp. - December 5, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotechnology company, is pleased to announce that it has filed a patent application for its Lidocaine Oral Thin Film Strip, with the Canadian Intellectual Property Office ("CIPO").

安大略省伯灵顿--(资讯文件CORP - 2024年12月5日) - Rapid Dose Therapeutics Corp.(CSE: DOSE)("RDT"或"公司"),是一家加拿大生物技术公司,欣然宣布已向加拿大知识产权局("CIPO")提交了其麻醉药物利多卡因口用薄膜条的专利申请。

Dentists commonly perform dental procedures using anesthesia administered through injection by needle, which is commonly preceded by a spray, gel, jelly, cream, or ointment. RDT is proud to announce a significant breakthrough in the form of Thin Film Strip for oral use.

牙医通常通过针头注射麻醉来进行牙科手术,注射通常前需要喷雾、凝胶、果冻、奶油或药膏。RDt自豪地宣布在口用薄膜条方面取得了重大突破。

Using dissolvable films allows dentists to place an oral lidocaine strip directly to the treatment area with enhanced precision, delivering anesthetic by reliably adhering to the oral mucosa upon contact. When the film dissolves, the lidocaine is held directly onto the area of interest by the mucoadhesive film components, ensuring maximum effectiveness. This pleasantly flavored strip has the ability not only to deliver a pain-free dental procedure but also helps reduce patient anxiety prior to the introduction of a local anesthetic. The Lidocaine Strip doesn't clog the suction tubes as it dissolves completely and is absorbed into the oral mucosa. In many cases, treatment can be effectively solely performed with the Lidocaine QuickStrip for rapid application and pain relief.

使用可溶解薄膜可以让牙医将口用利多卡因条直接放置在治疗区域,增强精确度,通过在接触时可靠地粘附于口腔粘膜来提供麻醉。当薄膜溶解时,利多卡因由粘附性薄膜元件直接保持在关注区域,确保最大效果。这种口味宜人的薄膜条不仅能够提供无痛的牙科手术,还能在局部麻醉引入之前帮助减少患者焦虑。利多卡因条在完全溶解并被口腔粘膜吸收时,不会堵塞吸引管。在许多情况下,治疗可以仅通过利多卡因快速条有效地进行,快速应用和缓解疼痛。

The strength of the Lidocaine QuickStrip can vary for other dental uses such a post-op pain control for surgery, stomatitis, oral lesion, painful oral ulcers, and traumatic injuries.

利多卡因快速条的力量在其他牙科使用中可能会有所不同,例如手术后的疼痛控制、口腔炎、口腔病变、疼痛性口腔溃疡和外伤。

The versatility of Lidocaine QuickStrip offers numerous advantages for both patients and practitioners. Developed and designed to reduce patient anxiety, The Lidocaine Strip boasts strong efficacy especially for patients who may feel nervous during dental visits. With its ease of administration, Lidocaine QuickStrip saves chair time for dentists—reducing the traditional needle administration process, which can take up to five minutes with conventional sprays and gels.

利多卡因快速条的多功能性为患者和从业人员提供了众多优势。为了减少患者焦虑而开发和设计的利多卡因条,具有强大的疗效,特别是对于在牙科就诊时可能感到紧张的患者。由于其易于施用,利多卡因快速条能为牙医节约更多的看诊时间——减少传统针头施用过程,这一过程可能需要长达五分钟,而传统喷雾和凝胶则需要更长时间。

"Lidocaine QuickStrip presents a cost-effective and scalable solution for the dental industry, and this patent application marks a significant advancement in our innovative QuickStrip Oral Thin Film drug delivery platform," stated Mark Upsdell, CEO of RDT. "We are advancing through R&D milestones to develop a diverse array of applications leveraging QuickStrip technology, aiming to enhance RDT's impact and set a new benchmark for patient comfort and making a meaningful difference in dentistry."

"利多卡因快贴为牙科行业提供了一种具有成本效益和可扩展的解决方案,此专利申请标志着我们创新的快贴口腔薄膜药物递送平台的重大进展," RDt 的首席执行官 Mark Upsdell 说道。"我们正在通过研发里程碑,开发多样化的应用,利用快贴技术,旨在提升 RDT 的影响力,为患者舒适度设定一个新的标准,并在牙科行业中产生有意义的变化。"

About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit .

关于快速药物治疗公司。
快速药物治疗是一家加拿大生物技术公司,通过创新彻底改变药物递送。公司的旗舰产品快贴是一种薄型口服溶解膜,可以融合无限种活性成分,包括营养保健品、药品和疫苗,能够快速送入血液,迅速发挥活性成分的作用。有关公司的更多信息,请访问。

Contacts:
Mark Upsdell, CEO
416-477-1052

联系方式:
马克·厄普斯戴尔,首席执行官
416-477-1052

RDT Investor Contact:
Investor Relations
investorrealtions@rapid-dose.com
416-477-1052

RDt投资者联系:
投资者关系
investorrealtions@rapid-dose.com
416-477-1052

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

关于前瞻性声明的警告说明:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "intend", "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

本新闻稿中的某些信息可能包含适用证券法意义上的前瞻性信息。本新闻稿中包含的任何不为历史事实的陈述可能被视为前瞻性陈述。前瞻性陈述通常以诸如“打算”、“可能”、“应该”、“预期”、“期待”、“潜在”、“相信”、“将”、“能够”、“计划”、“预期”等术语及这些术语的否定形式和类似表达来识别。包含前瞻性信息的陈述,包括但不限于关于使用QuickStrip产品交付方式交付设备和产品、产生经常性收入、RDt管理层对未来事件或结果的计划、估计、预测、展望、期望或信念,这些都被认为是基于目前可用的信息, RDt管理层认为这些是合理的。前瞻性陈述必然涉及已知和未知的风险,包括但不限于与一般经济条件相关的风险;不利的行业事件;市场营销费用;市场丧失;WLm协议的终止;涉及大麻的未来立法和监管发展;无法从内部和外部来源获取足够的资本,和/或无法以有利条款获取足够的资本;加拿大的大麻行业通常,所得税和监管事项;实施其业务战略的能力;竞争;货币和利率波动以及其他风险。读者应注意,前述列表并不详尽。不能保证前瞻性信息的陈述,尽管在准备时被RDt管理层认为是合理的,但会证明是准确的,因为不能保证其所依据的计划、意图或期望会发生。实际结果和未来事件可能与这些预期的前瞻性陈述有实质性差异。读者不应对前瞻性陈述过度依赖。本新闻稿中的前瞻性陈述明确受到该谨慎声明的限制。该新闻稿中的前瞻性陈述是在本新闻稿日期作出的,本公司明确否认更新或更改任何包含前瞻性信息的陈述或其基础的因素或假设的义务,无论是因新信息、未来事件还是其他原因,除非法律要求。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发